文献速递肝病

抑制mPGES-2通过血红素激活NR1D1改善NASH

Inhibition of mPGES-2 ameliorates NASH by activating NR1D1 via heme.
PubMed 文献 · Hepatology · 2022-08-08

本研究探讨微粒体前列腺素E合酶-2(mPGES-2)在非酒精性脂肪性肝病(NAFLD)中的作用及机制。采用高脂饮食或蛋氨酸胆碱缺乏饮食喂养的全身或肝细胞特异性mPGES-2缺陷小鼠,发现mPGES-2缺陷可减轻肝脏脂质蓄积及肝损伤、炎症和纤维化,其保护作用依赖于血红素受体NR1D1调控的CYP4A14降低和ACOT4升高,而非PGE2。mPGES-2抑制剂SZ0232在NAFLD治疗中证实有保护作用。

要点

  • mPGES-2缺陷可减轻NAFLD小鼠肝脏脂质蓄积及肝损伤、炎症和纤维化。
  • 保护作用依赖NR1D1调控的CYP4A14降低和ACOT4升高,不依赖PGE2。
  • mPGES-2抑制剂SZ0232在NAFLD治疗中显示保护作用。

核心结论

  • mPGES-2在NAFLD中具有致病作用,抑制mPGES-2在肝脂肪变性和脂肪性肝炎中具有治疗潜力。

研究设计与样本

  • 使用高脂饮食或蛋氨酸胆碱缺乏饮食喂养的全身或肝细胞特异性mPGES-2缺陷小鼠,评估mPGES-2在NAFLD中的作用。

主要发现

  • 与对照小鼠相比,mPGES-2缺陷小鼠肝脏脂质蓄积减少,肝损伤、炎症和纤维化减轻。
  • mPGES-2缺陷对NAFLD的保护作用依赖于NR1D1调控的CYP4A14降低和ACOT4升高,而非PGE2。
  • 血红素调控mPGES-2缺陷介导的NR1D1活性增加。
  • mPGES-2抑制剂SZ0232在NAFLD治疗中证实有保护作用。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD), a complex metabolic syndrome, has limited therapeutic options. Microsomal prostaglandin E synthase-2 (mPGES-2) was originally discovered as a prostaglandin E 2 (PGE 2 ) synthase; however, it does not produce PGE 2 in the liver. Moreover, the role of mPGES-2 in NAFLD remains undefined. Herein, we aimed to determine the function and mechanism of mPGES-2 in liver steatosis and steatohepatitis. APPROACH AND RESULTS: To evaluate the role of mPGES-2 in NAFLD, whole-body or hepatocyte-specific mPGES-2-deficient mice fed a high-fat or methionine-choline-deficient diet were used. Compared with control mice, mPGES-2-deficient mice showed reduced hepatic lipid accumulation, along with ameliorated liver injury, inflammation, and fibrosis. Furthermore, the protective effect of mPGES-2 deficiency against NAFLD was dependent on decreased cytochrome P450 4A14 and increased acyl-CoA thioesterase 4 levels regulated by the heme receptor nuclear receptor subfamily 1 group D member 1 (NR1D1), but not PGE 2 . Heme regulated the increased NR1D1 activity mediated by mPGES-2 deficiency. Further, we confirmed the protective role of the mPGES-2 inhibitor SZ0232 in NAFLD therapy. CONCLUSION: Our study indicates the pathogenic role of mPGES-2 and outlines the mechanism in mediating NAFLD, thereby highlighting the therapeutic potential of mPGES-2 inhibition in liver steatosis and steatohepatitis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zhong D, Cai J, Hu C, et al. Inhibition of mPGES-2 ameliorates NASH by activating NR1D1 via heme. Hepatology. 2022. PMID: 35839302. doi:10.1002/hep.32671

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。